Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
- 1Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
- 2Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
A Corrigendum on
Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
By Li Q, Ma F and Wang Jf (2023). Front. Oncol. 13:997314. doi: 10.3389/fonc.2023.997314
In the published article, there was an error in affiliation 1. Instead of “Department of Oncology, Zhengzhou University’s Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China”, it should be “Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China”.
Furthermore, there was an error in affiliation 2. Instead of “Department of General Surgery, Zhengzhou University’s Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China”, it should be “Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China”.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: advanced lung cancer inflammatory index (ALI), hepatocellular carcinoma, Immunotherapy, nomogram, prognosis
Citation: Li Q, Ma F and Wang J (2024) Corrigendum: Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. Front. Oncol. 14:1431058. doi: 10.3389/fonc.2024.1431058
Received: 11 May 2024; Accepted: 28 May 2024;
Published: 10 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Li, Ma and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qian Li, zlyyliqian3798@zzu.edu.cn; subbud@163.com